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Abstract
Background: Atypical ductal hyperplasia (ADH) is a common diagnosis in the mammographic era and a significant
clinical problem with wide variation in diagnosis and treatment. After a diagnosis of ADH on biopsy a proportion
are upgraded to carcinoma upon excision; however, the remainder of patients are overtreated. While ADH is
considered a non-obligate precursor of invasive carcinoma, the molecular taxonomy remains unknown.
Main text: Although a few studies have revealed some of the key genomic characteristics of ADH, a clear understanding
of the molecular changes associated with breast cancer progression has been limited by inadequately powered studies
and low resolution methodology. Complicating factors such as family history, and whether the ADH present in a biopsy is
an isolated lesion or part of a greater neoplastic process beyond the limited biopsy material, make accurate interpretation
of genomic features and their impact on progression to malignancy a challenging task. This article will review the
definitions and variable management of the patients diagnosed with ADH as well as the current knowledge of
the molecular landscape of ADH and its clonal relationship with ductal carcinoma in situ and invasive carcinoma.
Conclusions: Molecular data of ADH remain sparse. Large prospective cohorts of pure ADH with clinical follow-
up need to be evaluated at DNA, RNA, and protein levels in order to develop biomarkers of progression to carcinoma
to guide management decisions.
Keywords: Atypical ductal hyperplasia, Breast neoplasms, Ductal carcinoma in situ, Breast cancer progression, Clonal
relationship, Patient care management
Background
The term “benign breast disease” encompasses a hetero-
geneous group of non-malignant lesions (Fig. 1) [1–5].
With the introduction of population-based mammo-
graphic screening programs, there has been an increased
detection of these putative precursor lesions. While the
detection of invasive ductal carcinoma (IDC) by mam-
mographic screening programs has increased 1.6-fold,
the detection of benign lesions has increased two- to
four-fold [6], indicating that not all precursor lesions will
ever progress to malignancy. Indeed, a recent study with
a median of 12 years follow-up showed that only a
minority of women (143 among 698; 20%) with atypical
hyperplasia (AH; both atypical ductal hyperplasia (ADH)
and atypical lobular hyperplasia (ALH)) eventually pro-
gressed to malignancy even without any preventative
strategies [7]. Based on their study and other available
data the authors concluded that atypical hyperplasia
confers an absolute risk of subsequent breast cancer of
30% at 25 years of follow-up [7]. However, the studies
shown in Fig. 1 [1–5] show some heterogeneity in the
rate of a subsequent breast carcinoma event after a be-
nign biopsy. The variability of associated risk with each
type of lesion could be due to multiple factors, including
sample size (range 24–336 AH diagnoses), length of
follow-up (range 8–17 years), inclusion criteria (e.g., the
Nashville study [1] excluded patients who had breast
cancer within 6 months of the first biopsy), and in par-
ticular the criteria used for atypical hyperplasia diagnosis,
which is known to vary as discussed below. Given that
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each lesion will have variable potential for carcinoma de-
velopment [5] (Fig. 1), it is important to know which ones
are true precursors of breast cancer to facilitate appropri-
ate management. Although both forms of AH, ductal and
lobular, carry a similar long-term risk of developing meta-
chronous carcinoma [8, 9], in this review we will particu-
larly focus on ADH, which is histopathologically distinct
from ALH [3], presents a more common clinical issue,
and has a higher upgrade rate [7].
ADH is not only a risk factor for IDC, it is also consid-
ered to be a direct but non-obligate precursor to carcin-
oma [1]. Diagnosis of ADH carries a four- to fivefold
increased risk of developing breast cancer within 5 years
that is not limited to the ipsilateral breast [1, 10]. How-
ever, Hartmann et al. [7] pointed out that risk estimation
has not been calculated as cumulative incidence by the
current breast cancer risk prediction tools (such as Gail/
Breast Cancer Risk Assessment Tool, International Breast
Cancer Intervention Study (IBIS)), and that the lifetime
incidence is 25–30% according to multiple large retro-
spective studies, each with more than 300 AH (both
ductal and lobular) diagnoses [7–9, 11].
Strikingly, the risk associated with ADH is doubled
with family history, suggesting inherited factors are asso-
ciated with ADH development. Hoogerbrugge et al. [12]
showed that high risk histopathologic lesions, including
ADH (39%), were detected in almost 50% of the women
younger than age 40 years with a hereditary predisposition
for breast cancer who underwent prophylactic mastec-
tomy, not limited to only BRCA mutation carriers.
The occurrence of ADH in the general population
varies widely from 3% of benign biopsies [13] (based on
30,953 cases), to 8–10% [14, 15] (n = 3532), to 23% [16]
(n = 2833).These differences could come from the total
number of biopsies analyzed and/or when these biopsies
have been performed (pre/post-widespread mammo-
graphic screening). In the pre-mammographic era, biop-
sies would likely have been performed only for palpable
lesions with concomitant low frequency of ADH (2.1%
[17], n = 10,542). In the current era of mammographic
screening biopsies are additionally performed based on
micro-calcifications, for example; therefore, a higher
frequency of ADH could be observed [18]. These differ-
ences may also reflect geographical or temporal differ-
ences in incidence, as ADH is associated with hormone
replacement therapy (HRT), use of which varies widely
over time [13]. Moreover, the variations in ADH fre-
quency may suggest under- or over-diagnosis of ADH at
different centers due to differing definitions or variation
arising as a consequence of the number of slides sec-
tioned per specimen. For example, Page et al. reported
only 2.1% ADH in their cohort with, on average, one to
five slides per specimen (total original biopsies n =
10,542) [17] as opposed to 26 slides by de Mascarel et al.
Fig. 1 Forest plot showing histologic category of benign breast lesions and relative risk for breast cancer with 95% confidence interval. RR relative risk
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(23% detection rate) (n = 2833) [16]. In autopsy studies
in the general population, ADH was observed in the
breast of 3–13% of women [19], which could well be an
underestimate, given limited sampling techniques.
In this review, we focus on the definition, diagnosis, and
current management of ADH as well as its molecular
alterations. We also mention the strengths and limitations
of some previous studies and propose ideas for studies
that need to be undertaken in order to better understand
breast cancer development associated with ADH.
Definition of ADH
ADH resembles low nuclear grade ductal carcinoma in
situ (DCIS) with cytonuclear and architectural atypia but
with either partial involvement of the ducts and/or small
size for a diagnosis of DCIS. In ADH there are ducts
partially filled with abnormally uniform evenly spaced
cells with polarization [20] (Fig. 2). ADH and low nuclear
grade DCIS (LG DCIS) show not only morphological
similarities, including cytological and architectural fea-
tures, but also immuno-phenotypical overlap (both are
estrogen receptor (ER)- and progesterone receptor (PR)-
positive and HER2-negative) and especially genomic alter-
ations [21]. ADH has been defined as having “some but
not all the requisite features of DCIS” with an involvement
of ducts by an architecturally complex proliferation of
monotonous cells forming cribriform-like and/or micro-
papillary formation with a maximum of two separate
spaces [20, 22]. The cells might grow in arcades, rigid
bridges, or bars of uniform thickness, micro-papillae, solid
or cribriform patterns. The involved spaces might also
contain a population of cells with similar characteristics of
usual ductal hyperplasia (UDH) or residual normal epithe-
lium [22]. Due to their similar morphological features,
ADH and LG DCIS are difficult to reproducibly distin-
guish; therefore, one other feature was added to differenti-
ate between them—ADH is arbitrarily defined as having a
size of ≤ 2 mm [10, 20–22]. Unlike intermediate and high
grade DCIS, ADH typically lacks central necrosis and sig-
nificant nuclear atypia [1].
One of the major impediments to proper management
of ADH is the conflicting definitions of ADH and intra-
observer variability which make a definitive diagnosis
difficult [10, 23]. Ghofrani et al. [23] described instances
of the inconsistencies and disagreements of ADH diag-
nosis among 230 pathologists. For example, one of the
scenarios showed that although ADH is defined by hav-
ing a diameter ≤ 2 mm or only partially involved ducts,
when five ducts, each ≤ 2 mm, were involved, 37% of pa-
thologists diagnosed it as DCIS and when > 20 partially
involved ducts were involved more than 60% of patholo-
gists diagnosed it as DCIS and recommended excision
[23]. Multiple other studies showed a similar lack of con-
cordance in differentiating ADH from LG DCIS among
pathologists, ranging from 58 to 92% (reviewed by Walia
et al. [10]). However, when standardized published criteria
were followed, particularly with a set of provided teaching
slides, the concordance rate was satisfactory (71–92%, six
participants) [24]. Moreover, one study with nine partici-
pants showed not only lack of concordance between ADH
and LG DCIS but also between ADH and UDH; however,
this poor concordance can be improved by including data
from immuno-histochemical staining with multiple cyto-
keratins (CK) [25]. Particularly, basal type cytokeratins
(CK5/6) were found to be very effective for such differen-
tial diagnosis [22, 26]. Low nuclear grade neoplasia in the
breast, including ADH, typically shows diffuse strong
Fig. 2 Histological appearance of atypical ductal hyperplasia (40×)
(a) and low-grade ductal carcinoma in situ (40×) (b)
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nuclear ER positivity and lacks high molecular weight
cytokeratins, such as CK5/6 expression, in keeping with
proliferation of end-differentiated luminal cells, unlike
UDH (heterogeneous mosaic pattern). Myoepithelial-
specific markers such as p63 and myoid markers such as
SMA are helpful to demonstrate preservation of myoe-
pithelial cells at the epithelialstroma interface. Notably,
while myoepithelial marker positivity in the proliferative
pools is useful in the diagnosis of adenomyoepithelioma
and other myoepithelial lesions, this does not aid in the
differential diagnosis of epithelial hyperplasia versus epi-
thelial neoplasia/atypia [27]. It is important to note that
CK5/6 cannot distinguish ADH from LG DCIS as both
show uniformly negative staining for luminal cells [25].
Collectively, these studies suggest that a more objective
biomarker for the differential diagnosis of ADH and LG
DCIS would be highly desirable since extent alone cannot
differentiate an early neoplastic lesion that may not pro-
gress to malignancy from those that represent part of a
DCIS process that is underrepresented in the examined
specimen and are more likely to progress. Molecular stud-
ies could play an important role to identify such bio-
markers; however, given the above described lack of
concordance at assessing ADH [28], any studies related to
ADH need to include a strict review procedure by one or
more breast pathologists with sufficient experience before
inclusion into the study.
ADH diagnosis and management
ADH is usually first identified in a core needle biopsy
(CNB), and first designated as a “B3” lesion: i.e., of un-
certain malignant potential of the breast. The manage-
ment of patients diagnosed with ADH on CNB varies
not only because of the initial biopsy type/size but also
because of the variable reported “upgrade rate”. Upgrade
of ADH refers to the finding of cancer (DCIS/IDC) in
the surgical excision biopsy that was not present in the
CNB. One very recent review stated that 22–65% of
ADH diagnosed by CNB were upgraded to carcinoma
[29]. The surgical excision rate is lower (60%) if the
ADH was diagnosed by vacuum assisted biopsy (VAB),
since this technique is thought to be more efficient at
removing lesion areas than CNB [29]. While most up-
grades of ADH are DCIS, upgrades to IDC do happen
[30]. In terms of the management of the patients, some
clinicians prefer to observe patients diagnosed with
ADH. However, this option may put those patients at
risk of undertreatment. Given the high upgrade rate, it is
not surprising that the majority of clinicians suggest a
surgical excision after ADH diagnosis on CNB to rule
out concomitant malignancy. For example, if a patient
had an area of radiographic abnormality and her CNB
showed a focus of atypical cells in keeping with ADH
and not sufficient for the diagnosis of LG DCIS, it would
be preferable to perform an excision to examine the
whole area of abnormality. Because the abnormal radio-
logical mass might be due to a well-developed DCIS,
surgical excision could avoid missing a higher risk lesion
requiring more intensive treatment [31]. In this type of
upgrade scenario, presumably the most likely explan-
ation for missing a higher risk lesion from a CNB would
be sampling limitations. This highlights the important
clinical utility of identifying robust biomarkers that can
distinguish between pure ADH and ADH that is likely to
be associated with a synchronous LG DCIS and thereby
avoiding the need for recommending surgical excision
for all. Alternatives to surgical excision include treat-
ment with tamoxifen as this has been reported to reduce
the risk of developing breast cancer from 21 to 7.5% in
10 years (from 2459 ADH diagnoses) [32]. However, re-
cent studies on breast cancer prevention with endocrine
therapy show a very low rate of uptake and even lower
rate of persistence due to the side effects, even in
women at very high genetic risk [33].
Some parameters may be useful to take into consider-
ation before excision, such as the number of cores, type
of needle used, type of lesion, and lesion diameter [7,
10]. It has also been suggested to take into account the
number of the foci in the core and how much of the
radiographic lesion was removed, with multiple foci
requiring a greater area to be removed [34]. Similarly,
another recent paper [35] suggested that the radiographic
presence of residual lesions after CNB and the maximum
lesion size could be predictive of upgrades with 78%
sensitivity and 80% specificity. However, this study had
only a small and retrospective sample cohort (n = 151)
and included only those patients already recommended
for surgical excision. None of these parameters or sugges-
tions is clinically proven and prospective validation is
required to evaluate such prediction tools. Thus, the rec-
ommendation and current clinical practice is to perform
an open surgical excision on all ADH diagnosed on CNB
or VAB unless ADH is a single focus [29, 36]. This prac-
tice would certainly overtreat the majority of women diag-
nosed with ADH and clearly demonstrates the need to
identify a robust biomarker to avoid unnecessary surgery
and optimal management.
Risk prediction following ADH diagnosis
Unfortunately, risk prediction following ADH diagnosis
is controversial [7], and counseling and further screening
for these women diagnosed with ADH are therefore
probably not adequate. Indeed, Degnim et al. [8, 11]
showed that the 25-year risk of developing cancer asso-
ciated with ADH is at least 25%, and it could be as high
as 50–60% if the ADH is both multifocal and calcified
(n = 331). One possibility is that this combination indi-
cates a lesion already DCIS at a cellular biology level but
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lacking the extent to be diagnosed as such. Calcification
in their study was present in 70% of the ADH cases, and
calcification alone didn’t have a significant independent
association with higher risk [8, 11]. An elevated risk of
breast cancer associated with calcification of atypical
hyperplasia was, however, reported by Hutchinson et al.
(n = 210) [37]. In terms of multifocality, a very recent
case-control study from Nurses’ Health Studies found
that multifocality was only a significant risk factor for
ALH (n = 110) rather than ADH (n = 173) [3]; differ-
ences in sampling and the level of centralized pathology
review between the two studies are potential con-
founders for these observations. Although the multiple
foci of ADH were well defined by the pathologists to dis-
tinguish between ADH and LG DCIS in Degnim et al. [8,
11] and the Nurses’ Health Studies [3], the location of cal-
cification was not specified (intra-ductal versus stromal)
[8, 11] or was unknown [3]. As calcification is one of the
common features of ADH [16, 22], it would have been
really interesting to see if intra-ductal calcification and/or
stromal calcification correlate with different risk. The de-
gree of atypia can also vary in ADH, but this is not a fea-
ture that has been evaluated in terms of subsequent risk,
perhaps because of the difficulty in standardizing such a
measure across different pathologists.
Apart from the histologic variables, younger/pre-meno-
pausal women (< 45 years) are at higher risk of developing
metachronous carcinoma as found by several studies [8,
38, 39], particularly higher grade cancer [40]. The com-
plexities of analyzing focality, calcification, and atypia in
terms of how these are measured emphasizes the import-
ance of understanding the breast biology, as well as the
precursor versus risk indicator status of ADH. Given the
fact that only a fraction of ADH (9.8–30%) [7, 41] develop
metachronous carcinoma, a molecular marker of risk may
have the potential to be more objective than clinical symp-
toms or histopathological features alone for the manage-
ment of patients.
Thus far, despite the high risk of developing cancer asso-
ciated with ADH, attempts to identify clinicopathological
or molecular biomarkers to predict individual risk have
been unsuccessful. Risk reduction strategies remain varied,
from active surveillance at one end of the spectrum to
prophylactic mastectomy at the other.
Molecular features of ADH
Breast cancer is well known to be a genetic disease,
with very frequent somatic copy number changes, a
number of driver mutations such as in PIK3CA and
TP53, and widespread transcriptional deregulation [42].
While molecular studies of benign breast disease are
fewer, they suggest both similarities to and differences
from breast carcinoma.
Genetic events in pure ADH
Very few studies have described the molecular genetic
features of ADH (Table 1) and these are further limited
because most were carried out on small numbers of
samples using low resolution methodology, such as micro-
satellite marker-based loss of heterozygosity (LOH) or al-
lelic imbalance (AI) analysis and cytogenetic comparative
genomic hybridization (CGH). The latter has a genomic
resolution of 5–10 Mb, whereas most LOH studies were
carried out using only a few markers, which were chosen
based on the location of common regions of AI in IDC.
One of the major barriers to studying ADH is the limited
amount of DNA available, a problem reported by multiple
studies [43, 44]. This limitation can be overcome by using
in situ assays, such as fluorescence in situ hybridization
(FISH), but at the cost of being highly locus-specific.
An LOH study of 41 ADH samples at 15 genetic loci
selected based on the locations of frequently inactivated
tumor suppressor genes in IDC, such as TP53, RB1, and
BRCA1, reported that 42% of “pure” ADH (without syn-
chronous DCIS/IDC) showed LOH in at least one locus,
suggesting that inactivation of these tumor suppressor
genes might be an early neoplastic event and related to
the subsequent development of IDC [45]. This study
identified loss of 16q as an LOH “hot spot” in ADH and
also in low-grade DCIS and IDC. Loss of 16q was also
confirmed as a common event in breast cancer by other
studies (Table 1), signifying that this event might be par-
ticularly important in the early development of breast
cancer. Indeed, flow cytometry studies have suggested
that 15–44% of ADH are aneuploid, indicating that copy
number alterations are often present at this pre-
malignant stage [46–50]. A more sensitive FISH study
using nine chromosomal probes supported these obser-
vations, finding that all ADH had chromosomal aneu-
ploidy, and the number of cells with aneuploidy was
higher than in lesions without atypia, although less fre-
quent than in carcinomas [51]. In contrast, two other
FISH analyses observed aneuploidy in 1/5 and 0/2 ADH
using two and six probes, respectively, whereas carcin-
omas all carried aneuploidies [52, 53].
Using alternative methods, Gao et al. [54] detected copy
number aberrations in 15 pure ADH samples by array
CGH and found that although there were similar genetic
alterations among ADH, DCIS, and IDC, there were also
alterations unique to each lesion. Firstly, they found that
gain at 19p and losses at 2p, 6q, 11p, 12q, 22q, and Xq were
only present in DCIS and IDC, suggesting that these
changes might be a later event in breast cancer progression.
Secondly, ADH had a high prevalence of 17q gain [54], al-
though the number of cases studied was small. In addition,
this study is the only one in the literature in which ADH
showed more copy number changes than DCIS. This un-
usual feature, along with the pattern of CGH alterations
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with a high proportion of changes at telomeres, may sug-
gest an imperfect assay, particularly for ADH samples
where material would have been limited. Two other CGH
studies each showed several copy number gains (Table 1);
however, the sample sizes were just two (pure ADH) [55]
and three (synchronous) [56].
These genetic studies emphasize the difficulty in analyz-
ing small numbers of cases with varying definitions of
ADH, often leading to different conclusions. Nonetheless,
despite individual small sample sizes, across all LOH and
CGH studies, 16q loss remained the most common cyto-
genetic event in pure ADH, followed by 1q gain, with
other loci being gained and lost at relatively lower and
varying frequencies. In addition, collectively these studies
show that most pure ADH carry one or more large-scale
cytogenetic abnormalities.
ADH as a precursor lesion
As well as evaluating pure ADH, a common strategy has
been to study “synchronous” ADH found in the same
breast as carcinoma (DCIS or IDC). The goal of these
studies has been to establish whether ADH could be a
genetic precursor to carcinoma (and determine which
type of carcinoma), and to evaluate whether genetic events
are required for progression.
Early studies used LOH to investigate the clonal rela-
tionship between ADH and associated cancers; for ex-
ample, Larson et al. [44] performed a microsatellite
analysis of 45 ADH samples with co-existing DCIS or IDC
from 16 patients. These studies found that ~ 60% of the
cancer cases had a co-existing clonal ADH lesion. More
recently, next-generation sequencing approaches have
been applied, although only in small numbers of cases so
far. For example, Newburger et al. [57] showed that
atypical hyperplasia shared a common ancestor with the
carcinoma based on somatic mutations, although this was
based on only two patient samples [57]. Similarly, Weng
et al. [58] assessed the phylogenetic relationship between
early neoplasias, including ADH, and DCIS and IDC by
studying six breast cancer patients with concurrent
Table 1 Major genetic features of atypical ductal hyperplasia
Methoda Number
of samples
Number of loci
or genomic
resolution
Cases
with aberration
Average
cases altered
per locus
Location of copy
number gaina
Location of copy
number loss/LOH/AIa
SNVa Reference
LOH 10P 2 50% 38.9% NA 16q, 17p NA [43]
LOH 26P
25S
15 42%P
44%S
6.2%
9.5%
NA 11p, 13q, 16q,
17p, 17q
NA [45]
LOH 23S 14 NA 15% NA 8p,16q,17q NA [79]
LOH 16S 22 75% 13% NA 1q, 3p, 11p, 11q,
16q, 17p
NA [44]
LOH 31P 26 65% 6.1% NA 8q NA [67]
LOH total 131 (67P, 64S) 2–26 53%P, 70%S 15% NA 16q (24%), 13q (15%),
17q (12%), 11p (12%),
17p (10%)
NA
CGH 9P 5–10 Mb 55% NA 1q, 16p, 11q 16q, 17p, 20p NA [80]
CGH 2P 5–10 Mb 100% NA 1q, 3p, 6p, 10p, 11q,
12q, 13q, 16p, 17q,
20q, 8q, 14q, 15q
4q, 5q, 1p, 13q,
16q, 17p
NA [55]
CGH 3S 5–10 Mb 100% NA 3p, 8q, 15q, 16p,
20q, 22q
13q, 16q NA [56]
CGH 15P 5–10 Mb 93% NA 1p, 1q, 2q, 8q, 10p,
17q, 20q, 20p, 2q, Xp
8p, 9p, 11q, 13q,
14q, 16q, 21q, Xp
NA [54]
CGH total 29 80%P, 100%S NA 8q, 20q, 16p, 17q, 1q 16q, 13q, 17p, 8p NA
Targeted
sequencing
4 130–296
SNV/case
100% NA NA NA Lineage
heterogeneity
[58]
WGS 2 1 base pair 100% NA 1q gain early
neoplastic event
– ADH and
carcinoma shared
SNVs
[57]
FISHP 9 8 100% 45.6% 7, 8, 18 – – [51]
FISHS 13 1 54% NA Higher ERBB2 amplification
from ADH to DCIS to IDC
NA NA [65]
aLOH loss of heterozygosity, AI allelic imbalance, CGH comparative genomic hybridization, SNV single nucleotide variant, WGS whole-genome sequen-
cing, FISH fluorescence in situ hybridization, NA not available or not applicable. Gains are considered when chromosomal imbalance is > 1.25 and losses
are considered when it is < 0.8 of the normal allelic ratio. AI is considered when the imbalance is > 1.33 or < 0.75 of the normal allelic ratio. Any gains
or losses are reported when changes occurred in at least one sample of the cohort. P = pure ADH (no synchronous carcinoma), S = ADH with
synchronous carcinoma
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neoplasias (four with atypia). This analysis revealed con-
siderable lineage heterogeneity and the authors suggested
that the early neoplastic lesions and DCIS were not direct
precursors of the co-existing IDC, but rather independent
clonal proliferations of cells with a common ancestor.
Interestingly, they also found that some neoplasias showed
a mixed-lineage origin, referring to the samples whose
cells are geographically co-located but have originated
from at least two genetically diverse lineages (although
often still sharing an ancient common ancestor). The ac-
cumulated somatic mutations of those samples could not
be explained by a single lineage tree, suggesting existing
high intra-individual genetic heterogeneity, which was also
observed by Larson et al. [44]. Given that genetic hetero-
geneity may be a bad prognostic feature in several tumor
types [59], its detection in benign lesions could be relevant
for patient management. If multiple neoplastic or atypical
lesions were detected by high resolution imaging, phylo-
genetic analysis of carcinoma and concurrent neoplasia/
ADH might change the direction of the patients’ manage-
ment by treating or removing not only cancerous lesions,
but also the reservoir of genetically diverse neoplasias to
prevent recurrence.
These genetic studies to date support a role for ADH as
a precursor of carcinomas identified in the same breast,
but they do not explain the risk associated with ADH for
the contralateral breast. It has been noted in multiple
studies that ipsilateral recurrence is most common (al-
most twice that of contralateral) in the first 5 years after
ADH diagnosis; however, the long-term risk remains high
for both breasts [7, 9]. It is important to note that ipsilat-
eral recurrence is not limited to the initial site of diagnosis
of ADH and in cases where the carcinoma recurs at a dif-
ferent quadrant, it could be speculated that this would be
non-clonal. Indeed, this possibility is supported by Larson
et al., who noted that ADH in different tissue blocks to
the co-existing carcinoma were less likely to be clonal
(75% clonal when in the same block vs 27% when in differ-
ent blocks) [44]. Interestingly, they also observed the pres-
ence of ADH heterogeneity in 46% of cases when there
were multiple ADH foci in the same cancer-containing
breast, indicating independent origins of the lesions. ADH
may therefore also be a marker of elevated risk not associ-
ated with clonal recurrence. As suggested by a study of
field cancerization effect in epidermoid carcinoma [60],
ADH and other benign lesions could be the result of a
“field effect” where non-related tumors are co-located
within a cancer-prone tissue. Apart from germline predis-
position, the cause of such a field effect in the breast is
not yet known; however, at least for ER+ tumors, factors
suggested by epidemiological studies could play a role—
for example, parity, breast feeding, and mammographic
breast density [3]. Other environmental risk factors, such
as alcohol consumption, smoking, or obesity, could also
contribute to such a “field”. These micro-environmental
influencers could provide a possible explanation for the
initiation of multiple breast lesions over long periods of
time, their persistence, and their progression to carcin-
oma. Particularly, ADH in younger women could be the
result of an oncogenic insult and/or extreme susceptibility
for the proposed oncogenic estrogen metabolites associ-
ated with the premenopausal hormonal environment [8].
Studying the association of atypia with these characteris-
tics could give an insight into identifying patients with a
higher risk of recurrence. Interestingly, a very recent study
showed no association between mammographic breast
density and risk of recurrence in patients diagnosed with
atypical hyperplasia [14]. Breast density, therefore, despite
being a major indicator of an altered breast microenviron-
ment, appears not to influence subsequent progression to
carcinoma after ADH. Similarly, higher BMI, early menar-
che, and smoking are not associated with a higher risk of
developing invasive cancer after a previous breast benign
biopsy [61]. Further study is needed to evaluate the differ-
ent contributions of these factors for disease initiation as
distinct from disease progression. The role of the immune
system has barely begun to be investigated as a factor con-
trolling disease progression, but could well be crucial.
Early models of breast cancer development, which pro-
posed a direct linear progression from normal epithelium
to ductal hyperplasia to ADH to low-grade DCIS and then
to low- or high-grade IDC, are now considered to be over-
simplified [21]. Instead, distinct low- and high-grade mul-
tistep models of breast cancer progression have been
hypothesized [21]. The “low-grade like” progression path-
way is characterized by recurrent loss of 16q (> 75%),
gains of 1q; expression of hormone receptors (ER+, PR+),
lack of HER2 overexpression and a low-grade-like gene
expression signature [21, 62, 63]. The “high-grade-like”
progression pathway is characterized mainly by gains of
8q (75%) and 1q (60%), losses of 1p (60%), 8p (60%), and
17p (60%), and a luminal B, HER2, or basal-like mRNA
expression profile [21, 63]. Studies of breast cancer stem
cells also suggest that, apart from the claudin-low subtype,
the cell of origin for the other intrinsic breast cancer sub-
types may originate at different points along the luminal
progenitor lineage [64]. It remains unknown if distinct
precursors arise from these progenitors since many of the
molecular alterations are not necessarily exclusive to each
pathway. Where does ADH fit into this new paradigm?
Regarding ADH progression, a prevailing view is that
ADH is only a direct precursor of LG and ER-positive
carcinoma [21]; however, this is not supported entirely
by the literature. On one side, Larson et al. demon-
strated that clonality between ADH and synchronous
carcinoma was more likely when the carcinoma was low
grade and that ADH lacking any AI was most commonly
associated with high grade cancer, although these trends
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were non-significant [44]. However, at least two of the
clonal cases studied by Larson et al. must have been of
high grade, although this was not explicitly stated. In-
deed, few genetic studies have stated the grade of cancer
synchronous to ADH. In addition, the later development
of breast carcinoma associated with ADH is not limited
to LG cancer. Two recent studies [9, 40] showed that
about two-thirds of the recurrent breast carcinomas
were ER+ intermediate/high grade. It is noteworthy that
small subsets of patients diagnosed with ADH developed
ER− (9%) and/or HER2+ ductal carcinoma (7%) [40], in-
cluding ipsilateral recurrences. As the precursor of HG
DCIS and/or HG IDC is still unknown, a synchronous
ADH genomics study with LG and HG carcinoma and
including all intrinsic subtypes of carcinoma, along with
detailed histopathological features of the ADH, would be
highly desirable to determine the precursor relationship.
It would certainly aid in patient management if we could
identify the subsets of patients diagnosed with ADH that
might develop HG cancer and treat them accordingly. In
fact, after the accurate diagnosis of ADH, this question
is one of the most challenging unaddressed clinical ques-
tions regarding ADH. Degnim et al. [8] showed the im-
portance of both the number of foci of ADH and
calcification as features associated with a higher risk of
recurrence; however, they did not mention whether any
of these features also significantly correlated with grade
or ER status of the subsequent breast carcinoma. Cor-
relative studies of tumor type after ADH also do not ad-
dress the genetic relationship of recurrences to previous
ADH: at present, this is entirely unknown, but critical in
order to understand the natural history of ADH and to
guide therapy choices.
While genetic analysis of ADH with high-grade and/or
ER− carcinomas is underrepresented in the literature,
HER2 cases have been addressed through the use of FISH.
Interestingly, a FISH study of synchronous cases reported
that the amplitude of the amplification of ERBB2 increased
from ADH to DCIS to IDC [65]. Fifty-four percent of ADH
synchronous with HER2+ IDC showed low or moderate
ERBB2 amplification, suggesting ERBB2 amplification can
be involved early in breast oncogenesis but higher amplifi-
cation may be required for progression [65]. This result
supports ADH as a precursor lesion for HER2+ cancer,
consistent with the observation of HER2+ breast cancer
arising after an ADH diagnosis [9, 40].
Other studies of ADH synchronous to carcinoma have
also attempted to identify genetic events associated with
progression, similar to studies comparing pure DCIS to
DCIS synchronous with IDC, in which it has been ob-
served that pure DCIS have different molecular profiles
to synchronous DCIS, with the latter carrying more copy
number changes overall [66]. Similarly, when pure ADH
was compared to synchronous ADH, pure ADH showed
less AI compared to cases synchronous with DCIS or
IDC, although the power of the studies was limited [45,
67]. However, while DCIS was genetically very similar to
synchronous IDC [68, 69], the overlap between syn-
chronous ADH and carcinomas has shown that even
when clonally related (~ 60% of the time) co-existing
carcinomas often have additional genetic events [44]. In
addition, a sequencing study found that while few driver
point mutations were found, patients with atypical
hyperplasia shared aneuploidy events with the carcin-
omas, suggesting that copy number change, particularly
the 1q gain commonly observed in IDC [70], might be
an early driver of the neoplastic phenotype [57]. Their
findings also suggested that early neoplasias can harbor
sufficient driver aneuploidy events to progress into car-
cinoma, possibly with a combination of mutational load
and accumulated aneuploidy, as well as epigenetic and
stromal changes over time. A similar aneuploidy hypoth-
esis was proposed by Forsberg et al. [71], who observed
copy number changes in histologically normal epithelial
cells at uninvolved margins of IDC. However, these stud-
ies only included cases with synchronous carcinoma,
which may not be representative of atypical hyperplasia
without co-existing carcinoma. Overall no consistency in
specific genetic events can be attributed to progression.
This may reflect inter-tumoral genetic heterogeneity
and/or that the number and combination of drivers are
more important than the order of genetic events. It may
not be possible, therefore, to map specific genetic events
to the cancer phenotype, although as noted already, the
number of cases in the current literature is inadequate
to say whether this is indeed the case.
Transcriptional changes in ADH
As well as the genetic events described above, progression
to IBC from ADH may be evaluated by gene expression
differences, which can also reflect the influence of the
local environment. In order to understand the key driver
events in breast cancer progression, Brunner et al. [72]
carried out expression analysis of matched normal, ADH,
and cancer tissue from 16 patients to characterize tran-
scriptional differences. Interestingly, they found a pro-
oncogenic gene expression signature in early neoplasia
which was distinct from normal tissues and carcinoma
(DCIS/IDC) including up-regulation of ERBB2, FOXA1,
and GATA3 [72]. The ERBB2 mRNA overexpression was
not thought to be due to genomic amplification of the
ERBB2 locus since only three cases tested clinically
positive for HER2 amplification in the IDC. They sug-
gested that ERBB2 has a role in early stages of breast
cancer development independent of gene amplification
[72]. However, this conclusion is not supported by two
other immunohistochemistry-based studies, which did not
identify any overexpression of ERBB2 among 44 and 19
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atypical hyperplasias, respectively [73, 74]. The prognostic
and predictive factors of ERBB2 amplification and/or
overexpression should be studied extensively in a larger
cohort. GATA3 up-regulation was highly correlated with
ER positivity and FOXA1 expression in this study [72]. As
FOXA1 is one of the early events in the ER pathway
activation cascade, it might be possible that the oncogenic
nature of ER pathway activation is already established in
early neoplasia and continues to IDC as FOXA1 and
GATA3 are frequently mutated in ER+/luminal breast tu-
mors [42]. Additionally, Brunner et al. [72] reported that
several pathways influencing membrane transport, includ-
ing endocytosis by ABC transporters, fatty acid metabol-
ism, and phenylalanine metabolism, are highly enriched
already in early neoplasia compared to normal tissues.
Notably, these pathways do not encompass any well-
known oncogenes; thus, they should be explored further
to elucidate the mechanisms involved.
A second gene expression profiling study of ADH syn-
chronous with cancer (DCIS/IDC) (n = 31, eight with
ADH) showed that significant alterations are already
present in ADH and maintained in DCIS and IDC [75].
All ADH showed a grade 1 gene expression pattern and
clustered with low grade DCIS and IDC, confirming the
close relationship between ADH and low-grade carcin-
oma (DCIS/IDC) and that ADH have potential to pro-
gress into carcinoma [75]. Interestingly, GATA3 was
differentially expressed in this study, which supports the
finding of Brunner et al. [72]; however, FOXA1 and
ERBB2 were not reported. In addition, other key differ-
entially expressed genes and pathways found in Brunner
et al., such as the ABC transporters, were not found in
Ma et al. (except ABCA8 but with a low enrichment)
[75]. Only around 60 genes overlapped between these
two studies; however, there is a very poor correlation of
gene expression profiling reported previously between
microarrays and RNA sequencing with formalin-fixed
paraffin embedded tissues [76]. In general, however, both
studies showed that ADH was clearly different from nor-
mal breast epithelium, and additional differences were
noted on progression to carcinoma.
While these studies are informative for ADH present
in synchrony with carcinoma, the expression profiles of
pure ADH have not been adequately assessed in a suffi-
ciently powered study. One study did attempt to profile
pure ADH in comparison to ADH associated with car-
cinoma; however, the tissue used was taken adjacent to
the ADH lesion observed histologically, with no cer-
tainty that the ADH lesion was in fact present [77].
Nonetheless, some overlap was observed with genes dif-
ferentially expressed in Ma et al. [75] and the authors
proposed MMP-1 as a biomarker for progression to car-
cinoma. A detailed transcriptional study with a larger
cohort consisting of pure ADH with extensive patient
outcome data would be very powerful in order to iden-
tify new pathways for breast cancer prevention associ-
ated with ADH. Such studies are increasingly becoming
feasible, as the technology for transcriptional studies
from formalin-fixed, paraffin-embedded tissue becomes
more robust.
Conclusions
The increasing diagnoses of ADH as a consequence of
population-based mammographic screening have created
clinical dilemmas for treating physicians. Should ADH
always be excised or are other options viable? Understand-
ing the genetics of ADH might lead to effective strategies
to prevent development and progression of breast cancer
associated with ADH and shed light on the breast cancer
progression model, in particular the relationship of ADH
with non-low grade as well as ER− carcinoma. In addition
to synchronous cases, cases with neoplasia not associated
with cancer should be assessed in depth as these could be
informative for early diagnosis and preventative thera-
peutic strategies. The comparison of pure ADH with syn-
chronous ADH and cases where ADH was upgraded to
carcinoma on excision may be informative for develop-
ment of biomarkers to help aid in clinical treatment deci-
sions. Overall, the various limitations of all the previous
studies discussed in this review (small sample size, lacking
careful selection of ADH with and without carcinoma,
low resolution methodology, etc.) need to be overcome in
any future study of ADH. With the improvement of next-
generation sequencing technologies, a careful selection of
a larger cohort of ADH than studied to date (with and
without carcinoma of different grades), reviewed by an
experienced pathologist, would give an insight into early
breast cancer progression. Cases of ADH with at least
25 years follow-up should also be included to differentiate
between the cancerized and non-cancerized lineages [78],
whereby the former is the subset of ADH that could
progress to carcinoma while the latter subset would lack
progression capability even when harboring clonal genetic
events. The outcome of such a study could reduce the
burden of overtreatment associated with ADH.
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